Guillain–Barré syndrome and H1N1 (2009) pandemic influenza vaccination using an AS03 adjuvanted vaccine in the United Kingdom: Self-controlled case series

Vaccine ◽  
2011 ◽  
Vol 29 (45) ◽  
pp. 7878-7882 ◽  
Author(s):  
Nick Andrews ◽  
Julia Stowe ◽  
Rustam Al-Shahi Salman ◽  
Elizabeth Miller
Keyword(s):  
United Kingdom ◽  
Influenza Vaccination ◽  
Pandemic Influenza ◽  
Case Series ◽  
Guillain Barre Syndrome ◽  
Adjuvanted Vaccine ◽  
The United Kingdom ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

scholarly journals Incidence of Guillain-Barré Syndrome Is Not Associated with Influenza Vaccination in the Elderly

Vaccines ◽  
2020 ◽  
Vol 8 (3) ◽  
pp. 431
Author(s):  
Hankil Lee ◽  
Hye-Young Kang ◽  
Sun-Young Jung ◽  
Young-Mock Lee
Keyword(s):  
Influenza Vaccination ◽  
Case Series ◽  
The Elderly ◽  
Guillain Barre Syndrome ◽  
Medical Claim ◽  
Risk Period ◽  
Guillain Barré Syndrome ◽  
Previous Infection ◽  
Korean National Health Insurance ◽  
Guillain Barré

We aimed to analyze the incidence of Guillain-Barré syndrome (GBS) and its association with influenza vaccination (IV) in the elderly population. This study included 2470 patients hospitalized with GBS (G61.0) between 2014 and 2016 based on the Korean National Health Insurance Service (NHIS) claims data. We reviewed every medical claim in the 42 days preceding GBS diagnosis looking for precedent causes of GBS. To assess the relationship between IV and the development of GBS, data from the NHIS and the National Vaccination Registry were combined and analyzed. Using a self-controlled case series (SCCS) approach, we calculated the incidence rate ratio by setting the risk period as 42 days following vaccination. The annual background incidence of GBS was estimated at 4.15 per 100,000 persons. More than half of the patients with newly developed GBS had a previous infection or surgery. The incidence of GBS within 42 days of IV was estimated at 0.32 per 100,000 vaccinated persons. SCCS analysis showed that the risk of GBS was not significantly higher. While GBS can potentially develop from various infections, no association was found between GBS and IV. These results will contribute to developing an evidence-based vaccine policy that includes a clear causality assessment of adverse events.

scholarly journals Guillain-Barré Syndrome and Adjuvanted Pandemic Influenza A (H1N1) 2009 Vaccines: A Multinational Self-Controlled Case Series in Europe

PLoS ONE ◽  
2014 ◽  
Vol 9 (1) ◽  
pp. e82222 ◽  
Author(s):  
Silvana Romio ◽  
Daniel Weibel ◽  
Jeanne P. Dieleman ◽  
Henning K. Olberg ◽  
Corinne S. de Vries ◽  
...  
Keyword(s):  
Pandemic Influenza ◽  
Influenza A ◽  
Case Series ◽  
Guillain Barre Syndrome ◽  
Influenza A H1n1 ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

scholarly journals No Association Between Immunization and Guillain-Barré Syndrome in the United Kingdom, 1992 to 2000

2006 ◽  
Vol 166 (12) ◽  
pp. 1301 ◽  
Author(s):  
Richard A. Hughes ◽  
Judith Charlton ◽  
Radoslav Latinovic ◽  
Martin C. Gulliford
Keyword(s):  
United Kingdom ◽  
Guillain Barre Syndrome ◽  
The United Kingdom ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

scholarly journals Post-Infectious Guillain–Barré Syndrome Related to SARS-CoV-2 Infection: A Systematic Review

Life ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 167
Author(s):  
Pasquale Sansone ◽  
Luca Gregorio Giaccari ◽  
Caterina Aurilio ◽  
Francesco Coppolino ◽  
Valentina Esposito ◽  
...  
Keyword(s):  
Single Case ◽  
Case Reports ◽  
Case Series ◽  
Guillain Barre Syndrome ◽  
Response To Treatment ◽  
Comprehensive Overview ◽  
Fisher Syndrome ◽  
Immunomodulating Therapy ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

Background. Guillain-Barré syndrome (GBS) is the most common cause of flaccid paralysis, with about 100,000 people developing the disorder every year worldwide. Recently, the incidence of GBS has increased during the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) epidemics. We reviewed the literature to give a comprehensive overview of the demographic characteristics, clinical features, diagnostic investigations, and outcome of SARS-CoV-2-related GBS patients. Methods. Embase, MEDLINE, Google Scholar, and Cochrane Central Trials Register were systematically searched on 24 September 2020 for studies reporting on GBS secondary to COVID-19. Results. We identified 63 articles; we included 32 studies in our review. A total of 41 GBS cases with a confirmed or probable COVID-19 infection were reported: 26 of them were single case reports and 6 case series. Published studies on SARS-CoV-2-related GBS typically report a classic sensorimotor type of GBS often with a demyelinating electrophysiological subtype. Miller Fisher syndrome was reported in a quarter of the cases. In 78.1% of the cases, the response to immunomodulating therapy is favourable. The disease course is frequently severe and about one-third of the patients with SARS-CoV-2-associated GBS requires mechanical ventilation and Intensive Care Unit (ICU) admission. Rarely the outcome is poor or even fatal (10.8% of the cases). Conclusion. Clinical presentation, course, response to treatment, and outcome are similar in SARS-CoV-2-associated GBS and GBS due to other triggers.

Influenza vaccination and Guillain Barre syndrome☆

2003 ◽  
Vol 107 (2) ◽  
pp. 116-121 ◽  
Author(s):  
Mark R. Geier ◽  
David A. Geier ◽  
Arthur C. Zahalsky
Keyword(s):  
Influenza Vaccination ◽  
Guillain Barre Syndrome ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

SERIAL NERVE CONDUCTION STUDIES IN A GUILLAIN-BARRÉ SYNDROME VARIANT: THE EVOLUTION OF DEMYELINATING CHANGES

2015 ◽  
Vol 86 (11) ◽  
pp. e4.158-e4
Author(s):  
Catherine Morgan ◽  
Benjamin Wakerley ◽  
Geraint Fuller
Keyword(s):  
Nerve Conduction ◽  
Case Series ◽  
Pathological Process ◽  
Nerve Conduction Studies ◽  
Guillain Barre Syndrome ◽  
Facial Weakness ◽  
Guillain Barré Syndrome ◽  
Guillain Barré ◽  
Underlying Pathology ◽  
Serial Assessments

Guillain Barré syndrome (GBS) varies both in terms of clinical phenotype and underlying pathology. Serial assessments allow greater understanding of the pathophysiology. The evolution of neurophysiological changes is particularly helpful in distinguishing between demyelination and reversible axonal conduction failure.Bilateral facial weakness with distal paraesthesias is a rare subtype of GBS. In the largest case series 64% had abnormalities in motor and 27% in sensory conduction on single neurophysiological assessments; this was interpreted as a demyelinating neuropathy.We report an 18-year-old male with bilateral lower motor neurone facial weakness preceded by distal paraesthesias following a ‘flu-like illness. Examination of power and sensation was normal. Deep tendon reflexes were present. Cerebrospinal fluid showed albuminocytologic dissociation. By 6 weeks his facial weakness had almost completely resolved without treatment.Serial nerve conduction studies were performed. The first study (day 4) found prolonged distal motor latency and delayed F waves in posterior tibial and common peroneal nerves; normal sensory studies. Second study (day 18) found distal motor latencies and F waves had increased in upper and lower limb nerves. Third study (day 60) found improvement but abnormalities remained with changes similar to the first study.The neurophysiological changes became more marked while he improved clinically. These serial studies confirmed the primary pathological process of this GBS variant to be demyelination.

Sign in / Sign up

Export Citation Format

Share Document